ClinicalTrials.gg
CompletedNCT03372473Updated Dec 13, 2017

Montelukast and Loratadine in Children With Asthma

A Phase 3 interventional study of Montelukast mixed with Loratadine and Montelukast in Asthma in Children, sponsored by Innovacion y Desarrollo de Estrategias en Salud. Completed. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2017-12-13.

Sponsored by Innovacion y Desarrollo de Estrategias en Salud · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2016, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

Randomized controlled trial in 80 children with mild to persistent moderate asthma, who were randomized to receive montelukast 5mg + loratadine 5mg vs. montelukast 5mg + placebo for loratadine to evaluate the efficacy in terms of improvement of symptoms. Secondary outcome was the days off without the use of rescue medication; reduction of levels of cysteinyl leukotrienes (Cys-LTS), nitric oxide (FeNO), intracellular adhesion molecule type 1 (ICAM-1) and interleukin 8 (IL-8) in condensed exhaled air; the improvement of day and night symptoms; the reduction in the frequency of night awakenings; the improvement in the quality of life; the percentage of related adverse events; the need to use systemic steroids; the number of visits to the emergency department secondary to the presence of an asthma attack; the number of hospitalizations secondary to asthma attacks; and the improvement in the percentage of FEV1 in relation to the predicted.

Read the detailed description

Asthma is a disease with increasing prevalence worldwide that produces significant deterioration of the quality of life in children and development of important complications and economic, social impact. Considering the concept of a common airway (coexistence of asthma and rhinitis), joint management initiatives with anti-asthmatics and anti-histamines have been published. The primary objective of this clinical trial is to evaluate the efficacy and safety of the use of montelukast + loratadine in children with asthma on the improvement of symptoms and secondarily to evaluate the impact on a) the days off without the use of rescue medication; b) reduction of levels of cysteinyl leukotrienes (Cys-LTS), nitric oxide (FeNO), intracellular adhesion molecule type 1 (ICAM-1) and interleukin 8 (IL-8) in condensed exhaled air; c) the improvement of day and night symptoms; d) the reduction in the frequency of night awakenings; e) the improvement in the quality of life; f) the percentage of related adverse events; g) the need to use systemic steroids; h) the number of visits to the emergency department secondary to the presence of an asthma attack; i) the number of hospitalizations secondary to asthma attacks; and j) the improvement in the percentage of FEV1 in relation to the predicted. We included 80 children from 6 to 12 years old, any sex, with mild to moderate persistent asthma, after signing an informed consent letter by parents or guardians or signing the child's consent (> 8 years). Children with chronic diseases associated with the disease of interest were excluded (heart disease, nephropathy, liver disease of any kind); with any other lung disease other than asthma; with a history of hypersensitivity to montelukast or loratadine or with a history of concomitant use of medications that interact significantly with montelukast or loratadine

02

Conditions studied

  • Asthma in Children

Browse trials for

03

In context

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

This study's enrollment of 80 is close to the median of 79 across 3,346 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Innovacion y Desarrollo de Estrategias en Salud is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 6 to 12 years old
  • Any sex
  • Persistent mild to moderate asthma
  • Signature of letter by parents or guardians
  • Letter of assent of the minor for children over 9 years of age

Exclusion criteria

Exclusion Criteria:

  • Chronic pathologies associated with the disease of interest (heart disease, nephropathy, liver disease of any kind)
  • Any other lung disease other than asthma
  • History of to montelukast or loratadine
  • Concomitant use of medications that interact significantly with montelukast or loratadine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Montelukast mixed with Loratadine

    Montelukast 5mg mixed with Loratadine 5mg one dose a day

    Drug: Montelukast mixed with Loratadine

  • Active comparator
    Montelukast

    Montelukast 5mg one dose per day

    Drug: Montelukast

Interventions

  • DrugMontelukast mixed with Loratadine

    Montelukast 5mg mixed with Loratadine 5mg, one dose per day

  • Montelukast 5mg

06

What researchers measure

Primary outcomes

  1. Free of symptoms

    Number of days free of symptoms associated to asthma episodes

    Time frame: 10 weeks

Secondary outcomes

  1. Free of rescue medication

    Number of days free for use of rescue medications

    Time frame: 10 weeks

  2. Reduction of airway inflammatory profile

    Measurement of inflamatory biomarkers in exhaled respiratory air

    Time frame: 10 weeks

  3. Reduction of awakenings

    Frequency of nocturn awakenings

    Time frame: 10 weeks

  4. Quality of Life

    Changes in PedsQL during the treatment

    Time frame: 10 weeks

  5. Emergency visits

    Number of emergency visits secondary to asthma crisis

    Time frame: 10 weeks

  6. Adverse Events

    Frequency of reported adverse events

    Time frame: 10 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. doi: 10.1164/rccm.200406-710ST. No abstract available. PubMed 15817806 ↗
  • Carpagnano GE, Spanevello A, Sabato R, Depalo A, Palladino GP, Bergantino L, Foschino Barbaro MP. Systemic and airway inflammation in sleep apnea and obesity: the role of ICAM-1 and IL-8. Transl Res. 2010 Jan;155(1):35-43. doi: 10.1016/j.trsl.2009.09.004. PubMed 20004360 ↗
  • Carraro S, Corradi M, Zanconato S, Alinovi R, Pasquale MF, Zacchello F, Baraldi E. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J Allergy Clin Immunol. 2005 Apr;115(4):764-70. doi: 10.1016/j.jaci.2004.10.043. PubMed 15805996 ↗
  • Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, Zacchello F, Baraldi E. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol. 2004 Feb;113(2):257-63. doi: 10.1016/j.jaci.2003.10.046. Erratum In: J Allergy Clin Immunol. 2004 Apr;113(4):676. PubMed 14767439 ↗
  • Massingham K, Fox S, Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care. 2014 Jan-Feb;28(1):51-62. doi: 10.1016/j.pedhc.2012.11.005. Epub 2013 Jan 9. PubMed 23312367 ↗
  • Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004 Mar;113(3):415-9. doi: 10.1016/j.jaci.2003.11.034. PubMed 15007339 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Feb 2016, 0 months.

Of 32 non-industry phase 3 interventional studies under Asthma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 0 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Dec 13, 2017
StartActual
Jan 10, 2016
Primary completionActual
Feb 1, 2016
CompletionActual
Jun 30, 2017
Last update
Dec 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03372473
Lead sponsor
Innovacion y Desarrollo de Estrategias en Salud
Collaborators
National Institute of Pediatrics, Mexico, Laboratorios Senosiain, S.A. de C.V.
Responsible party
Pedro Gutierrez Castrellon (Head of Translational Research Center on Mother-Child Health, Innovacion y Desarrollo de Estrategias en Salud) — Principal investigator
First posted
Dec 13, 2017
Start date
Jan 10, 2016
Primary completion
Feb 1, 2016
Completion
Jun 30, 2017
Last update
Dec 13, 2017

Study contacts

Pedro Gutierrez Castrellon, MD
principal investigator · Hospital General Dr. Manuel Gea Gonzalez

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion